Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Adoptive immune therapy using EBV-specific CTL]

K Kuzushima1, T Morishima

  • 1Department of Pediatrics, Nagoya Ekisaikai Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative effectiveness of immunotherapeutic regimens for untreated advanced non-small-cell lung cancer in real-world clinical practice: a Japanese cancer registry cohort study.

ESMO real world data and digital oncology·2026
Same author

Identification of a naturally processed HLA-Cw7-binding peptide that cross-reacts with HLA-A24-restricted ovarian cancer-specific CTLs.

Tissue antigens·2015
Same author

Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.

Leukemia·2015
Same author

Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H.

Gene therapy·2014
Same author

HLA-restricted presentation of WT1 tumor antigen in B-lymphoblastoid cell lines established using a maxi-EBV system.

Cancer gene therapy·2012
Same author

HapMap SNP Scanner: an online program to mine SNPs responsible for cell phenotype.

Tissue antigens·2012
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Adoptive immunotherapy using Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTL) shows promise for treating EBV-associated cancers and infections, particularly in transplant patients. This approach leverages T cell advancements for immune control of EBV.

Area of Science:

  • Immunology
  • Virology
  • Oncology

Context:

  • Epstein-Barr virus (EBV) is linked to various malignancies.
  • Effective immune control strategies are crucial for managing EBV-associated diseases.
  • Advances in T cell biology and culture techniques enable new therapeutic approaches.

Purpose:

  • To review the current status and future potential of adoptive immunotherapy using EBV-specific cytotoxic T lymphocytes (CTL).
  • To discuss the application of EBV-specific CTL therapy in EBV-associated lymphoproliferative disorders post-bone marrow transplantation.
  • To highlight the use of EBV-specific CTL for treating severe chronic active EBV infection.

Summary:

  • Adoptive transfer of EBV-specific CTL is a viable immunotherapy for EBV-associated conditions.

Related Experiment Videos

  • This therapy has shown efficacy in patients undergoing bone marrow transplantation and those with chronic active EBV infection.
  • The review covers clinical applications and discusses future directions for EBV-targeted CTL immunotherapy.

    • Impact:

    • Provides a comprehensive overview of EBV-specific CTL immunotherapy.
    • Demonstrates the clinical relevance of T cell-based therapies for viral-associated malignancies.
    • Informs future research and clinical strategies for combating EBV-driven diseases.